These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 10850448)

  • 21. Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice.
    Kiaris H; Schally AV; Nagy A; Sun B; Armatis P; Szepeshazi K
    Br J Cancer; 1999 Nov; 81(6):966-71. PubMed ID: 10576652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Indirect antiproliferative effect of the somatostatin analog octreotide on MIA PaCa-2 human pancreatic carcinoma in nude mice.
    Weckbecker G; Raulf F; Bodmer D; Bruns C
    Yale J Biol Med; 1997; 70(5-6):549-54. PubMed ID: 9825482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of proliferation of small intestinal and bronchopulmonary neuroendocrine cell lines by using peptide analogs targeting receptors.
    Kidd M; Schally AV; Pfragner R; Malfertheiner MV; Modlin IM
    Cancer; 2008 Mar; 112(6):1404-14. PubMed ID: 18224665
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice.
    Kiaris H; Schally AV; Nagy A; Szepeshazi K; Hebert F; Halmos G
    Eur J Cancer; 2001 Mar; 37(5):620-8. PubMed ID: 11290438
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Laminin alpha1 chain in human renal cell carcinomas and integrin-mediated adhesion of renal cell carcinoma cells to human laminin isoforms.
    Rissanen J; Korhonen M; Lehto VP; Virtanen I
    J Pathol; 2003 Jun; 200(2):157-67. PubMed ID: 12754736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Growth inhibition of experimental non-Hodgkin's lymphomas with the targeted cytotoxic somatostatin analogue AN-238.
    Keller G; Engel JB; Schally AV; Nagy A; Hammann B; Halmos G
    Int J Cancer; 2005 May; 114(5):831-5. PubMed ID: 15609311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray.
    Li Y; Tang Y; Ye L; Liu B; Liu K; Chen J; Xue Q
    J Cancer Res Clin Oncol; 2003 Jan; 129(1):43-51. PubMed ID: 12618900
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of Ki-67 in a renal cell carcinoma severe combined immunodeficiency disease mouse model is associated with induction of apoptosis and tumour growth inhibition.
    Kausch I; Jiang H; Ewerdwalbesloh N; Doehn C; Krüger S; Sczakiel G; Jocham D
    BJU Int; 2005 Feb; 95(3):416-20. PubMed ID: 15679806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone-releasing hormone analogues AN-152 and AN-207.
    Engel JB; Keller G; Schally AV; Nagy A; Chism DD; Halmos G
    Fertil Steril; 2005 Apr; 83 Suppl 1():1125-33. PubMed ID: 15831285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of human non-small cell lung cancers with a targeted cytotoxic somatostatin analog, AN-162.
    Treszl A; Schally AV; Seitz S; Szalontay L; Rick FG; Szepeshazi K; Halmos G
    Peptides; 2009 Sep; 30(9):1643-50. PubMed ID: 19524629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of gastrin releasing Peptide receptor in renal cell carcinomas: a potential function for the regulation of neoangiogenesis and microvascular perfusion.
    Heuser M; Schlott T; Schally AV; Kahler E; Schliephake R; Laabs SO; Hemmerlein B
    J Urol; 2005 Jun; 173(6):2154-9. PubMed ID: 15879878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
    Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
    Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice.
    Prewett M; Rothman M; Waksal H; Feldman M; Bander NH; Hicklin DJ
    Clin Cancer Res; 1998 Dec; 4(12):2957-66. PubMed ID: 9865906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
    Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor effect of parathyroid hormone-related protein neutralizing antibody in human renal cell carcinoma in vitro and in vivo.
    Talon I; Lindner V; Sourbier C; Schordan E; Rothhut S; Barthelmebs M; Lang H; Helwig JJ; Massfelder T
    Carcinogenesis; 2006 Jan; 27(1):73-83. PubMed ID: 16081513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro.
    Songgang L; Jiyu L; Gongwei ; Yingbin L; Yiyu Q; Zhiwei Q
    Hepatogastroenterology; 2009; 56(94-95):1253-60. PubMed ID: 19950772
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124].
    Seitz S; Buchholz S; Schally AV; Jayakumar AR; Weber F; Papadia A; Rick FG; Szalontay L; Treszl A; Köster F; Ortmann O; Hohla F
    Anticancer Drugs; 2013 Feb; 24(2):150-7. PubMed ID: 23080077
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro.
    Pawlikowski M; Lawnicka H; Pisarek H; Kunert-Radek J; Radek M; Culler MD
    J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Crucial role for somatostatin receptor subtype 2 in determining the uptake of [111In-DTPA-D-Phe1]octreotide in somatostatin receptor-positive organs.
    Hofland LJ; Lamberts SW; van Hagen PM; Reubi JC; Schaeffer J; Waaijers M; van Koetsveld PM; Srinivasan A; Krenning EP; Breeman WA
    J Nucl Med; 2003 Aug; 44(8):1315-21. PubMed ID: 12902423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.